Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Rhea-AI Summary

Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant bacterial infections, announced that CEO Dr. Deborah Birx will present at the 5th Annual Phage Futures Annual Meeting in Boston, MA. The presentation is scheduled for 1:15pm ET on November 19th, 2024.

Argus Session date unavailable

-11.61% session move Open Argus

Details

News Market Reaction – ARMP

The recorded move for ARMP in the trading session of this news was -11.61%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS ANGELES, Nov. 19, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Dr. Deborah Birx, Chief Executive Officer, will deliver a presentation at 1:15pm ET at the 5th Annual Phage Futures Annual Meeting, which is being held November 19^th in Boston, MA.

For more information: https://phagefuturesusa.com/events/phage-futures-2024

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.

Media Contacts:

At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928 x234

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-that-ceo-dr-deborah-birx-will-deliver-a-presentation-at-the-5th-annual-phage-futures-annual-meeting-302309391.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Dr. Deborah Birx presenting at the Phage Futures Annual Meeting for ARMP?

Dr. Deborah Birx is presenting at 1:15pm ET on November 19th, 2024, at the 5th Annual Phage Futures Annual Meeting in Boston, MA.

What is Armata Pharmaceuticals (ARMP) main focus?

Armata Pharmaceuticals is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections.

Where is the 5th Annual Phage Futures Meeting for ARMP being held?

The 5th Annual Phage Futures Meeting is being held in Boston, MA.